CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...